Beleave Inc. (CSE:BE), a diversified biotech company with a purpose-built ACMPR licensed cannabis facility in Hamilton, Ontario and patient services clinics operating across Ontario under the Medi-Green brand, today announced the launch of an expanded shareholder communications initiative designed to provide improved visibility into Beleave’s current and planned operations. The initiative was prompted by an increase in shareholder inquiries, the Company’s desire for increased transparency for its stakeholders and the recent growth in its operations, highlighted by both the acquisition of the Medi-Green patient services business and receipt of its ACMPR sales license.
“The initiative is a multi-channel approach,” commented Beleave CEO Andrew Wnek, “As the industry continues to grow we feel that increasing our visibility in a transparent fashion will not only add comfort to our respected shareholder base but allow for productive discussion between shareholders and company management.”
The program is comprehensive and includes a redesign of the corporate website, the development of the investor relations portal, consistent shareholder update videos, quarterly investor conference calls with Company management, an active blog with in-house contributors, and an expanded social media strategy. In order execute on the aforementioned programs, the Company will seek to increase its shareholder communications with the launch of new features each month. The corporate website will include a new investor relations newsroom which will include real time press release dissemination, an active corporate blog featuring industry trends, XBRL data, and automatic posting of public filings. The newsroom will also feature corporate videos including consistent shareholder update videos featuring officers, directors and key personnel.
In support of its shareholder relations initiative, the Company retained two leading corporate communications firms, Storyboard Communications and, most recently, Link Media. Both firms act at arm’s length to the Company and are paid a monthly cash retainer or per published PR piece. To the knowledge of the Company, neither Storyboard nor Link Media owns any of the Company’s securities. Further, beyond those transactions disclosed on SEDI.ca, the Company has no knowledge of any directors trading the Companies securities within the last 90 days. Since the beginning of May, Link Media has arranged for dissemination of two third party research articles independent from the Company while allowing the Company to retain editorial control to ensure consistency across all articles and the monitor that published material was derived from the Company’s public filings on www.sedar.com. “Rolling out this type of program will allow the Company to have consistent, relevant news flow allowing investors to digest information in multiple ways,” continued Wnek. “In the long run this consistent news flow should play a role in combating short-selling common in the Cannabis industry.”
CSE Short information is published on a bi-weekly basis can be found at http://thecse.com/trading/market-activity/activity-summaries/short-positions. The Company believes the primary reason for its recent positive share position to be a decrease in short-selling against and the Company’s shares recently receiving DTC eligibility on the OTCQX, rather than the impact of the s articles arranged by Link Media.
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.
This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
SOURCE Beleave Inc.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.